NCT06926868

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2025-09-11Est. Completion: 2028-03-13

Enrollment target: 500 participants

Locations

Local Institution - 0303, Hot Springs, Arkansas, United States
Helios Clinical Research, Cerritos, California, United States
Local Institution - 0307, Cerritos, California, United States
Local Institution - 0308, Cerritos, California, United States
Local Institution - 0309, Cerritos, California, United States
Local Institution - 0311, Long Beach, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
Local Institution - 0358, Stanford, California, United States
Local Institution - 0289, Aurora, Colorado, United States
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
Local Institution - 0296, Pembroke Pines, Florida, United States
Local Institution - 0294, Atlanta, Georgia, United States
Northside Hospital, Atlanta, Georgia, United States

Breast CancerAnthracycline Related Cardiotoxicity in Breast CancerVirtual RealityTrastuzumab

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experienc…

Richmond, United StatesEst. completion Jul 30, 2026

Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant g…

Daphne, United StatesEst. completion Aug 8, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.